Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-139123
Filing Date
2024-12-20
Accepted
2024-12-20 17:00:04
Documents
1
Period of Report
2024-12-18

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3150
  Complete submission text file 0000950170-24-139123.txt   4914
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Issuer) CIK: 0001789972 (see all company filings)

EIN.: 813867811 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O GENOCEA BIOSCIENCES, INC. 100 ACORN PARK DRIVE 5TH FLOOR CAMBRIDGE MA 02140
Business Address
SUMER JACQUELYN L (Reporting) CIK: 0001844824 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 241568733